ATE59409T1 - Herstellung von oberflaechen-hepatitis-b-antigen in hefe. - Google Patents

Herstellung von oberflaechen-hepatitis-b-antigen in hefe.

Info

Publication number
ATE59409T1
ATE59409T1 AT82304513T AT82304513T ATE59409T1 AT E59409 T1 ATE59409 T1 AT E59409T1 AT 82304513 T AT82304513 T AT 82304513T AT 82304513 T AT82304513 T AT 82304513T AT E59409 T1 ATE59409 T1 AT E59409T1
Authority
AT
Austria
Prior art keywords
yeast
hepatitis
hbsag
antigens
gene
Prior art date
Application number
AT82304513T
Other languages
English (en)
Inventor
Ronald A Hitzeman
Arthur D Levinson
Daniel G Yansura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23149637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE59409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE59409T1 publication Critical patent/ATE59409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT82304513T 1981-08-31 1982-08-26 Herstellung von oberflaechen-hepatitis-b-antigen in hefe. ATE59409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29823681A 1981-08-31 1981-08-31
EP82304513A EP0073657B1 (de) 1981-08-31 1982-08-26 Herstellung von Oberflächen-Hepatitis-B-Antigen in Hefe

Publications (1)

Publication Number Publication Date
ATE59409T1 true ATE59409T1 (de) 1991-01-15

Family

ID=23149637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82304513T ATE59409T1 (de) 1981-08-31 1982-08-26 Herstellung von oberflaechen-hepatitis-b-antigen in hefe.

Country Status (10)

Country Link
EP (1) EP0073657B1 (de)
JP (1) JP2511394B2 (de)
AT (1) ATE59409T1 (de)
AU (1) AU560122B2 (de)
DE (1) DE3280284D1 (de)
GB (1) GB2104902B (de)
HK (1) HK37494A (de)
IE (1) IE56711B1 (de)
NZ (1) NZ201705A (de)
ZA (1) ZA826251B (de)

Families Citing this family (347)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340806B1 (de) * 1981-08-04 1995-05-31 The Regents Of The University Of California Synthese von menschlichen Virusantigenen durch Hefe
AU560472B2 (en) * 1981-08-25 1987-04-09 Celltech Limited Yeast expression vectors
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
EP0105149B1 (de) * 1982-08-16 1990-05-16 Science and Technology Agency, Minister's Secretariat, Director of Finance Division Hepatitis-B-Virus-Gen enthaltendes rekombinantes Plasmid, mit diesem rekombinanten Plasmid transformierte Hefe und Herstellung von Hepatitis-B-Virus-Oberflächenantigen
IL69202A (en) * 1982-09-08 1991-08-16 Smith Kline Rit Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
DE3382547D1 (de) * 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US5089398A (en) * 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8314961D0 (en) * 1983-05-31 1983-07-06 Kingsman A J Dna sequence
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
JPS60192591A (ja) * 1984-03-12 1985-10-01 Japan Found Cancer 成人ｔ細胞白血病ウイルス抗原ポリペプチド
JPS60196185A (ja) * 1984-03-19 1985-10-04 Chemo Sero Therapeut Res Inst 形質転換酵母の培養方法
DE3587759T2 (de) * 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4880734A (en) * 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
EP0171908A3 (de) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis-B-Virus-Oberflächenantigen und dessen Herstellung
JPS6170989A (ja) * 1984-09-13 1986-04-11 Takeda Chem Ind Ltd 組み換えｄｎａおよびその用途
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US7393949B1 (en) * 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
JP2594535B2 (ja) * 1984-11-30 1997-03-26 サントリー株式会社 高発現ベクターおよびその利用
EP0225887B1 (de) * 1985-04-08 1994-06-08 Amgen Inc. Verfahren und hybridpromotor zur steuerung der exogenen gentranskription
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1993012815A1 (fr) * 1991-12-27 1993-07-08 Gensci Limited Procede d'obtention d'un antigene de surface recombine de l'hepatite b, antigene et vaccin a base de celui-ci
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US6015660A (en) * 1995-01-06 2000-01-18 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6077510A (en) * 1995-01-06 2000-06-20 Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6113905A (en) * 1995-01-06 2000-09-05 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
IL126383A0 (en) 1996-04-01 1999-05-09 Genentech Inc Apo-2li and apo-3 apoptosis polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
JP3394540B2 (ja) 1997-01-31 2003-04-07 ジェネンテク・インコーポレイテッド Ｏ−フコシルトランスフェラーゼ
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1003856A1 (de) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
EP0927266A1 (de) 1997-07-11 1999-07-07 The University Of North Texas Health Science Center At Fort Worth Das escherichia coli csrb gen, davon kodierter rns, und verfahren zu deren anwendung
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
PT1015587E (pt) 1997-09-18 2008-07-31 Genentech Inc Polipéptido dcr3, um homólogo de tnfr
EP1967587A1 (de) 1997-10-10 2008-09-10 Genentech, Inc. APO-3-Liganden
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
DE69840051D1 (de) 1997-10-29 2008-11-06 Genentech Inc Durch wnt-1 induzierbare gene
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
EP1045906B1 (de) 1998-01-15 2008-10-15 Genentech, Inc. Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE69932247T2 (de) 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
EP2319929A1 (de) 1998-12-23 2011-05-11 Genentech, Inc. Mit IL-1 in Zusammenhang stehende Polypeptide
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
EP1666494A1 (de) 1999-12-01 2006-06-07 Genentech, Inc. Sekretierte und Transmembran-Polypeptide und für diese kodierende Nukleinsäuren
EP1239869B1 (de) 1999-12-20 2013-08-28 Immunex Corporation Tweak rezeptor
EP1897944B1 (de) 1999-12-23 2011-08-10 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
IL149893A0 (en) 1999-12-30 2002-11-10 Genencor Int Trichoderma reesei xylanase
DE60137829D1 (de) 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
JP2003528071A (ja) 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2042597B1 (de) 2000-06-23 2014-05-07 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004502665A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
WO2003002122A1 (en) 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
BR0212070A (pt) 2001-08-29 2004-09-28 Genentech Inc ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
EP1572130A4 (de) 2002-07-08 2008-07-02 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
EP2277532A1 (de) 2002-09-11 2011-01-26 Genentech, Inc. Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
DE60335497D1 (de) 2002-09-13 2011-02-03 Cornell Res Foundation Inc Ergillus-phytasen
EP1578364A4 (de) 2002-09-16 2011-06-08 Genentech Inc Zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
EP2500438A3 (de) 2002-09-25 2012-11-28 Genentech, Inc. Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
ATE546521T1 (de) 2002-10-04 2012-03-15 Firmenich & Cie Sesquiterpene synthasen und verwerdungsmethoden
EP1576137A4 (de) 2002-10-29 2010-06-30 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1592777A4 (de) 2003-02-01 2008-06-04 Tanox Inc Verfahren zur erzeugung hochaffiner antikörper
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
US7442785B2 (en) 2003-07-24 2008-10-28 The University Of Kentucky Research Foundation Sesquiterpene synthase gene and protein
ATE554108T1 (de) 2003-07-25 2012-05-15 Amgen Inc Verfahren bezüglich ldcam und crtam
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL2295073T3 (pl) 2003-11-17 2014-09-30 Genentech Inc Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
EP1771474B1 (de) 2004-07-20 2010-01-27 Genentech, Inc. Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
ES2343746T3 (es) 2005-01-07 2010-08-09 Diadexus, Inc. Composiciones de anticuerpo ovr110 y metodos de uso.
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2618878C (en) 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
EP3023497A1 (de) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2-integrin-antikörper und deren verwendungen
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
PL1969127T5 (pl) 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2010569A4 (de) 2006-03-20 2009-09-09 Xoma Technology Ltd Für gastrin spezifische humane antikörper, materialien und methoden
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
CN101479295A (zh) 2006-05-04 2009-07-08 健泰科生物技术公司 涉及zpa多肽的方法和组合物
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
CA2656558A1 (en) 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
EP3018144A1 (de) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-spezifischer antikörper und verwendungen davon
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
BRPI0716680A2 (pt) 2006-11-02 2013-09-24 Daniel J Capon "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo"
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
KR20140119831A (ko) 2006-12-07 2014-10-10 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2683423C (en) 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
CA2704973A1 (en) 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
EP2220116B1 (de) 2007-11-12 2012-09-05 Theraclone Sciences, Inc. Zusammensetzungen und verfahren zur therapie und diagnose von grippe
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
ES2542308T3 (es) 2008-03-10 2015-08-04 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
EP3208612B1 (de) 2008-04-09 2019-09-18 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
US8815794B2 (en) 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
NO2337846T3 (de) 2008-09-26 2018-06-16
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
NZ592436A (en) 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
US20120027722A1 (en) 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
AU2010229675B2 (en) 2009-03-27 2016-02-25 Academia Sinica Methods and compositions for immunization against virus
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
US8765431B2 (en) 2009-07-23 2014-07-01 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
CN102656266B (zh) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
AR078986A1 (es) 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
MX2012009809A (es) 2010-02-23 2012-11-23 Sanofi Sa Anticuerpos anti - integrina alfa2 y sus usos.
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EP4492053A3 (de) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Verfahren zur reinigung von polypeptiden
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
KR101768118B1 (ko) 2010-06-25 2017-08-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 기도 감염의 치료를 위한 방법 및 약학 조성물
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
EP3556396B1 (de) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
WO2012036884A2 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
CA2814023C (en) 2010-10-08 2018-01-16 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
EP2624852B1 (de) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Diagnostische und therapeutische verwendungen von moesinfragmenten
EP2624856B1 (de) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Moesinfragmente zur verwendung zur diagnose von immun-thrombozytopenie
JP5868410B2 (ja) 2010-10-08 2016-02-24 シャンハイ クーシン バイオテック カンパニー，リミテッド 再生不良性貧血と関連しているモエシン断片
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
CN103282492A (zh) 2010-10-29 2013-09-04 奥利里克斯股份有限公司 修饰的瓦伦烯合酶多肽、编码核酸分子及其用途
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2675478A4 (de) 2011-02-14 2015-06-10 Theraclone Sciences Inc Zusammensetzungen und verfahren zur therapie und diagnose von grippe
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
RS67639B1 (sr) 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
JP6138815B2 (ja) 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
EP2841087B1 (de) 2012-04-27 2017-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antagonisten gegen den vaskulären endothelialen wachstumsfaktor und verfahren zu deren verwendung
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
EP2880159A1 (de) 2012-07-30 2015-06-10 Allylix, Inc. Für nukleinsäuremoleküle codierende sclareol- und labdendioldiphosphatsynthasepolypeptide und ihre verwendung
WO2014037376A1 (en) 2012-09-04 2014-03-13 C5 Ligno Technologies In Lund Ab Stereoselective biosynthesis in microbial host cells
BR112015011462A2 (pt) 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
BR112015012968A2 (pt) 2012-12-07 2017-09-12 Danisco Us Inc composições e métodos de uso
DK2929022T3 (en) 2012-12-07 2017-02-13 Danisco Us Inc COMPOSITIONS AND METHODS OF USE
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
SI2968467T1 (sl) 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Pripravki z zmanjšano oksidacijo
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
AU2014243700B2 (en) 2013-03-13 2019-01-24 Genentech, Inc. Formulations with reduced oxidation
EP2968587A2 (de) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
HUE035866T2 (en) 2013-03-14 2018-05-28 Evolva Inc Valencene synthase polypeptides, coding nucleic acid molecules and their use
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
DK2968495T3 (da) 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
AR095348A1 (es) 2013-03-15 2015-10-07 Genentech Inc Medios de cultivo celular y métodos de producción de anticuerpos
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG10202002334PA (en) 2013-12-17 2020-05-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
BR112016013741A2 (pt) 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
ES2694857T3 (es) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
SI3116486T1 (sl) 2014-03-14 2020-07-31 Biomolecular Holdings Llc Hibridni imunoglobulin, ki vsebuje nepeptidilno vezavo
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
EP3191526B1 (de) 2014-09-12 2023-02-22 The Board of Trustees of the Leland Stanford Junior University Agonistenmoleküle des wnt-signalwegs
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
EP3201334A1 (de) 2014-09-30 2017-08-09 Danisco US Inc. Zusammensetzungen mit beta-mannanase und verfahren zur verwendung
EP3201330A1 (de) 2014-09-30 2017-08-09 Danisco US Inc. Zusammensetzungen mit beta-mannanase und verfahren zur verwendung
EP3201332A1 (de) 2014-09-30 2017-08-09 Danisco US Inc. Zusammensetzungen mit beta-mannanase und verfahren zur verwendung
WO2016054185A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
EP3221360A1 (de) 2014-11-17 2017-09-27 F. Hoffmann-La Roche AG Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
WO2016090546A1 (en) 2014-12-09 2016-06-16 Wentao Zhang Nbp158 and uses thereof
US20180002683A1 (en) 2014-12-18 2018-01-04 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
US20170362621A1 (en) 2014-12-18 2017-12-21 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016127057A1 (en) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
ES2810700T3 (es) 2015-05-29 2021-03-09 Hoffmann La Roche Metilación del promotor de PD-L1 en cáncer
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
CA3007491A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
EP3397287B8 (de) 2015-12-30 2025-07-23 F. Hoffmann-La Roche AG Formulierungen mit reduziertem abbau von polysorbat
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
US11767362B1 (en) 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
EP3974451A3 (de) 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen erkrankungen
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
DK3559234T3 (da) 2016-12-20 2021-11-15 Novozymes As Rekombinante gærstammer til pentosefermentering
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP4230649A3 (de) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
TWI897843B (zh) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
LT3743088T (lt) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
AU2019291890A1 (en) 2018-06-29 2020-12-17 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies for use in treating autoimmune disease
CA3106625A1 (en) 2018-07-16 2020-01-23 The Board Of Trustees Of The Leland Stanford Junior University Frizzled specific wnt agonists and antagonists
SG11202100601TA (en) 2018-08-08 2021-02-25 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
EP3857230B1 (de) 2018-09-21 2023-06-07 F. Hoffmann-La Roche AG Diagnosemethoden für dreifach-negativen brustkrebs
MA53980A (fr) 2018-10-23 2022-01-26 Consejo Superior Investigacion Anticorps spécifiques de l'apoj glycosylée et leurs utilisations
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
AU2020267874A1 (en) 2019-05-09 2021-10-28 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021164744A1 (en) 2020-02-19 2021-08-26 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
MA59827B1 (fr) 2020-05-26 2024-10-31 Boehringer Ingelheim International Gmbh Anticorps anti-pd-1
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
WO2022064494A2 (en) 2020-09-23 2022-03-31 Yeda Research And Development Co. Ltd. Methods and compositions for treating coronaviral infections
KR102546738B1 (ko) 2021-01-04 2023-06-22 씨제이제일제당 주식회사 글루타메이트-시스테인 리가아제 변이체 및 이를 이용한 글루타치온 생산방법
KR102593542B1 (ko) 2021-06-10 2023-10-26 씨제이제일제당 주식회사 슈퍼옥사이드 디스뮤테이즈 1 변이체 및 이를 이용한 글루타치온 또는 그 유도체의 생산방법
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4238988A1 (de) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antikörper gegen sars-cov-2 und verwendungen davon
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
DK171727B1 (da) * 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
GR76274B (de) * 1981-08-04 1984-08-04 Univ California

Also Published As

Publication number Publication date
EP0073657A1 (de) 1983-03-09
NZ201705A (en) 1986-03-14
GB2104902A (en) 1983-03-16
JP2511394B2 (ja) 1996-06-26
HK37494A (en) 1994-04-29
DE3280284D1 (de) 1991-02-07
GB2104902B (en) 1985-04-24
AU560122B2 (en) 1987-04-02
AU8779782A (en) 1983-03-10
JPS58109427A (ja) 1983-06-29
IE56711B1 (en) 1991-11-06
IE822086L (en) 1983-02-28
EP0073657B1 (de) 1990-12-27
ZA826251B (en) 1983-09-28

Similar Documents

Publication Publication Date Title
DE3280284D1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
HUT57266A (en) Process for producing new antigenes
EP0171908A3 (de) Hepatitis-B-Virus-Oberflächenantigen und dessen Herstellung
DE3584866D1 (de) Hybridpartikel-immunogene.
DE3280186D1 (de) Synthese von menschlichen viralen antigenen mit hilfe von hefe.
IL90035A0 (en) Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
ES8600059A1 (es) Procedimiento para la preparacion de un plasmido recombinante insertado con el gen del virus de la hepatitis b.
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
IL90161A0 (en) Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
AU584580B2 (en) Hepatitis B virus vaccine
EP0068719A3 (de) Desoxyribonukleine Säuren, deren Herstellung und Verwendung
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
EP0062574A3 (de) Synthese von Virusproteinen
AU8557491A (en) Method for obtaining recombinant surface antigen of hepatitis b virus (hep b) of higher immunogenic capacity and use thereof in a vaccine preparation
AU530195B2 (en) Vaccine for active immunization containing hepatitis b surface and/or e -antigens
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
JPS6467191A (en) Recombinant dna plasmid having integrated hepatitis b virus gene, transformed animal cell, hepatitis b viral surface antigen protein and production thereof
GR3036125T3 (en) Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.
KR900001845A (ko) 복합 프로모터를 이용한 효모 발현 벡터에 의한 b형 간염 바이러스 표면항원들의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time
RZN Patent revoked